EWING, N.J.-- (BUSINESS WIRE) -- Antares Pharma, Inc. (Amex:AIS) today announced that Dr. Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the Merriman Investor Summit 2009 on Tuesday, November 10, 2009 at 11:00 am ET (Eastern Time). The conference will be held at the Sofitel Hotel in New York City. A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/mcm12/ais/. The webcast will be archived for 90 days following the presentation.

About Antares Pharma (www.antarespharma.com)

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The company’s subcutaneous injection technology platforms include Vibex^TM disposable pressure-assisted auto injectors, Valeo^TM/Vision® reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceuticals Industries, Ltd that includes Tev-Tropin® human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the company’s lead product candidate, Anturol™, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder), is currently under evaluation in a pivotal Phase 3 trial. Antares also has a partnership with BioSante that includes LibiGel® (transdermal testosterone gel) in Phase III clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.